MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to GlobalData, Phase II drugs for Metastatic Transitional (Urothelial) Tract Cancer have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MHB-036C’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MHB-036C overview

MHB-036C is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), pancreatic cancer Ductal adenocarcinoma (PDAC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), ovarian cancer (OC), carcinoma (BC), gastric cancer (GC), castration-resistant prostate cancer (CRPC) and sweat gland carcinoma (SGC), metastatic transitional (urothelial) tract cancer, ureter cancer, bladder cancer, urethral cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, metastatic ovarian cancer, triple-negative breast cancer, human epidermal growth factor receptor 2 negative breast cancer, human epidermal growth factor receptor 2 positive breast cancer, metastatic castration-resistant prostate cancer, endometrial cancer. It is being developed based on SuperTopoi ADC platform It is administered through intravenous route. It acts by  targeting TROP-2.

For a complete picture of MHB-036C’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.